FDA’s second rejection ends Intercept’s NASH aspirations FDA/Regulatory, R&D Thursday, the FDA denied Intercept Pharmaceuticals’ application for its obeticholic acid tablets, which the New Jersey biopharma was proposing to treat patients with pre-cirrhotic liver fibrosis due to non-alcoholic steatohepatitis. Read more June 23, 2023/by BioSpace https://www.pharmalive.com/wp-content/uploads/2021/08/Ipsen-Voluntarily-Withdraws-FDA-Submission-for-FOP-Drug-BioSpace-8-13-21.jpeg 350 625 BioSpace https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png BioSpace2023-06-23 11:39:532023-06-23 11:39:53FDA’s second rejection ends Intercept’s NASH aspirations
